< Back

Goodbody Health Inc.

AQSE Growth Market -
Goodbody Health (Canadian Securities Exchange: GDBY), is an established health and wellness company that operates within the United Kingdom and Europe as a trusted distributor and retailer of quality, accredited wellness products and diagnostic services to provides a unique ‘frontline’ healthcare service in the local community and enable customers to manage their health care digitally. It also has world-class ISO accredited CBD extraction and laboratory testing capabilities. It operates under the mantra ‘Know More. Live Better’ To provide healthcare testing services in the local community.

goodbodyhealth.com
Symbol Ccy Code Bid Ask Share Price (Mid) Previous Close Volume Last Traded
GDBY GBX 1.2 1.5 1.35 1.35 30000 24.06.22

MiFID II compliant pre- and post-trade transaction data is available here. The data is delayed by at least 15 minutes and will be refreshed every 15 minutes. Publication of trades in equity securities that are large in scale compared to normal market size and illiquid non-equity securities may be delayed if the trade is eligible for deferred publication in accordance with the trading rules of Aquis Stock Exchange and MiFIR. Further details as to when the publication of a trade may be deferred are set out in the trading rules which are available here.

Key Information

  
Market Cap: £4,926,989
ISIN:CA3821591011
Par:
Inst Type:Ordinaries
Symbol:GDBY
MIFID Status:MTF
Tradable securities in issue:364,962,152
Sector:Health Care Equipment & Services
% daily price change:0.00%

Latest Trades

Date & Time Volume Price
24.06.22  |  12:27:17300001.4
20.06.22  |  11:50:56500001.5
20.06.22  |  09:40:326658701.5
20.06.22  |  08:04:3045141.22
17.06.22  |  11:58:58611751.35
17.06.22  |  08:10:47500001.3
17.06.22  |  08:10:28500001.3
16.06.22  |  12:29:48304921.24
15.06.22  |  15:58:247615761.434
14.06.22  |  14:29:27250001.1
View all trades >

Latest Announcements

Date & Time Title
20.06.22  |  07:00:00Goodbody Health Inc. - Genetic Risk Testing Cancer & Cardiovascular
16.06.22  |  07:00:00Goodbody Health Inc. - Care Quality Commission Registration Granted
10.06.22  |  13:00:00Goodbody Health Inc. - De-list from CSE, Re-domicile, Change of Adviser
26.05.22  |  07:00:00Goodbody Health Inc. - Launch of the Health “MOT” diagnostic test
25.05.22  |  07:00:00Goodbody Health Inc. - Goodbody publishes highest quarterly profit in Q1
03.05.22  |  07:00:00Goodbody Health Inc. - Audited Results to 31 December 2021
11.04.22  |  07:00:00Goodbody Health Inc. - Granted Home Office Controlled Drugs Licence
31.03.22  |  13:00:00Goodbody Health Inc. - Goodbody products on FSA Novel Foods Register
10.03.22  |  07:00:00Goodbody Health Inc. - Strong 2021 revenue continuing into 2022
08.03.22  |  07:00:00Goodbody Health Inc. - Goodbody Health rolls out blood testing technology
View all announcements >

Financial Information

Performance

Earnings per share of -2.87p for 12/2020 has grown from -4.77p in 12/2019 or 40% over the period.

Earnings per share   % growth (1)
   
 12/2020-40%
   
Average over 2 periods+-20%
Strength in EPS trend ±
Low
High

(1) % growth is year on year % change in EPS.

Basic earnings per share are earnings from continuing and discontinued operations that are attributable to current equity holders.

Business Insight

Costs to Revenues ratio of 3.1 in 12/2020 has declined from 3 in 12/2019. Operating costs over the period have increased at a faster pace than the Revenues have increased.

Cost to Revenue ratio (2)   Multiple to Revenue
   
 12/20193.0x
 12/20203.1x
   
Average multiple over 2 periods+3.0x
Strength of cost to revenue relationship ±
Low
High

(2) Costs include selling and admin, depreciation, amortisation and other operating costs.

Valuation

Financial Metric
Price multiple to metric
Relationship strength between metric and share price ±
  
EBITDA-3.2x
EBIT-2.9x
NI-3.1x
FCF-5.7x
DPS-
Assets1.8x
CE2.2x

The Relationship Strength is statistical measure of how close the data is to a line of best-fit line between share price and the metric shown. It is scaled between zero (no relationship) and 5 (strong relationship).

+ In cases of change in accounting period length, the average is for the last 3 periods. In all cases, it is dependent on published available data and may be for periods shorter than 3 years

± The ‘Strength’ bar shows the strength of the statistical linear relationship of the metrics shown in the chart over the last three periods of data.

Click here to download a glossary of terms.

All data provided by Fregnan.

Further Fregnan Data >

Click here to download a glossary of terms.

All data provided by Fregnan.

Further Fregnan Data >
Last results date:     31.12.20
Enterprise Value £14.57m
EV/EBITDA (3.19)
EV/EBIT (2.89)
   
PE Ratio (1.45)
PEG -
Dividend Yield -
Free Cash Yield (37.96)%

Click here to download a glossary of terms.

All data provided by Fregnan.

Further Fregnan Data >
31.12.19
(£'000)		 31.12.20
(£'000)
Income Statement    
Revenue 1,4491,994
Operating Income (EBIT) (3,553)(5,042)
Net Income (3,798)(4,659)
     
Balance Sheet    
Cash 1,9931,289
Total Debt 621500
Total Liabilities 1,0501,925
Total Equity 3,5016,284
     
Operating Margin (245.12)%(252.85)%
EPS - Basic (4.77)p(2.87)p
EPS - Growth -(39.88)%
Dividend Per Share --
Average Shares Outstanding 79.60m162.45m
     
ROA -(73.01%)
ROCE -(94.08%)
ROE -(95.22%)

Click here to download a glossary of terms.

All data provided by Fregnan.

Further Fregnan Data >
31.12.19
(£'000)		 31.12.20
(£'000)
Revenue 1,4491,994
Cost of Revenue 695871
Depreciation & Amortisation 260471
Gross Profit 495652
Other Operating Expenses 4,0485,695
Operating Income (EBIT) (3,553)(5,042)
Net Interest Expense 11-
Unusual Expense (incl. Exceptionals) 233(48)
Non-Operating Expense -208
Profit (pre-tax) (3,798)(4,787)
Taxation -128
Other Expenses and Minortity Interest --
Net Income (3,798)(4,659)

Click here to download a glossary of terms.

All data provided by Fregnan.

Further Fregnan Data >
31.12.19
(£'000)		 31.12.20
(£'000)
Cash from Operations (2,613)(2,348)
Cash from Investing (493)2,412
Cash from Financing 1,356(184)
Other Miscellaneous --
Net Cash Flow (1,750)(120)

Click here to download a glossary of terms.

All data provided by Fregnan.

Further Fregnan Data >
31.12.19
(£'000)		 31.12.20
(£'000)
Current Assets 2,7002,888
Non-Current Assets 1,8515,321
Total Assets 4,5528,210
Current Liabilities 6001,442
Non-Current Liabilities 451483
Total Liabilities 1,0501,925
Net Assets 3,5016,284
Total Equity 3,5016,284

Click here to download a glossary of terms.

All data provided by Fregnan.

Further Fregnan Data >

Address

Business Address

Goodbody Health Inc., The Blue Building, Stubbs Lane, Beckington Frome, Somerset, BA11 6TE, United Kingdom.

Email: enquires@goodbodyhealth.com

Phone: +44 (0) 20 7971 1255

Registered Address

1055 West Georgia Street, 1500 Royal Centre, PO Box 11117, Vancouver, BC, V6E 4N, Canada.

Contacts

Corporate Adviser

Peterhouse Capital Ltd, 3rd Floor, 80 Cheapside, London, United Kingdom.

Email: info@pcorpfin.com

Phone: +44 (0)20 7469 0930

Registrar

Computershare Investor Services PLC, The Pavilions, Bridgwater Road, Bristol, BS13 8AE, United Kingdom.

Email: web.queries@computershare.co.uk

Phone: 0370 703 6191

Research


Know More - Live Better